CD274 and neoplasm: In the study by Dirik et al. [79], where 168 heavily pretreated patients with locally advanced or MBC, including 58 patients with TNBC, received avelumab, a trend toward a higher ORR was seen in patients with PD-L1+ versus PD-L1− tumor-associated iCs in the overall population (16.7% vs. 1.6%, respectively), as well as in the TNBC subgroup (22.2% vs. 2.6%, respectively).